



Feidhmeannacht na Seirbhíse Sláinte, Seirbhís Aisíocaíochta Cúraim Phríomhúil  
Bealach amach 5, M50, An Bóthar Thuaidh, Fionnghlas  
Baile Átha Cliath 11, D11 XKF3  
Fón: (01) 864 7100 Facs: (01) 834 3589

Health Service Executive, Primary Care Reimbursement Service  
Exit 5, M50, North Road, Finglas,  
Dublin 11, D11 XKF3  
Tel: (01) 864 7100 Fax: (01) 834 3589

Ryan O'Meara, T.D.  
Dáil Éireann,  
Leinster House,  
Kildare Street,  
Dublin 2.

6<sup>th</sup> March 2025

PQ: 7166/25

**To ask the Minister for Health the supports that are available to an individual diagnosed with type 2 diabetes and advised to acquire a CGM sensor; and if she will make a statement on the matter. -Ryan O'Meara**

Dear Deputy O'Meara,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 7166/25), which you submitted to the Minister for Health for response.

The Health Information and Quality Authority (HIQA) published the rapid Health Technology Assessment of Continuous Glucose Monitoring (CGM) in Adults with Type 1 Diabetes Mellitus on 29th September 2023. The published document can be found at <https://www.hiqa.ie/reports-and-publications/health-technology-assessment/rapid-healthtechnology-assessment-continuous>.

A single reimbursement application system for Continuous Glucose Monitoring (CGM) sensors came into effect on 1st December 2023. Due to the budget impact associated with these, the HSE established a single reimbursement application system for all CGM sensors on the Reimbursement List. This reimbursement application system will apply to any future CGM sensors reimbursed under Community Drug Schemes.

Currently reimbursement support is available for patients with Type 1 Diabetes Mellitus, in line with Circular 033/23 (attached). Clinicians can apply through the secure portal for reimbursement support of CGM sensors to be considered under a person's community drug scheme eligibility.

Reimbursement of CGM at this point in time is for patients with Type I Diabetes Mellitus who have required insulin from the outset. Reimbursement does not extend to other cohorts who were not considered as part of the HIQA HTA.

If a prescriber wishes, the outcome of a negative decision can be appealed directly via email to the HSE Medicines Management Programme at [mmp@hse.ie](mailto:mmp@hse.ie), or a new application can be submitted via the online application system. Appeals must be made by the patient's clinician and should include any additional information to support the unmet clinical need for CGM sensors.

Appeals are reviewed on a case-by-case basis, reviewing the information provided in the initial online application and the information in the appeal submission to the HSE Medicines Management Programme. The final reimbursement recommendation is communicated back to the clinician via email or the online application system.

Yours sincerely,

Suzanne Doyle  
Primary Care Reimbursement Service

**The Health Service Executive operates the General Medical Services Scheme, which includes Medical Cards and GP Visit Cards, under the Health Act 1970, as amended. It has established a dedicated contact service for members of the Oireachtas specifically for queries relating to the status of Medical Cards and GP Visit Cards applications, which the Deputy / Senator may wish to use for an earlier response. Tel: 01-8647180 / email: [Oireachtas.pcrs@hse.ie](mailto:Oireachtas.pcrs@hse.ie)**